In a move to boost the bilateral trade relationship between Malaysia and India, Malaysian Biotechnology Corporation (BiotechCorp), the lead development agency for the biotechnology industry in Malaysia, kicked off their first business development engagement for 2009 in Hyderabad and Chennai with the Indian media members and industry participants. The latest updates on the Indian-Malaysian investment initiatives were shared to address the current challenging economic climate.
BiotechCorp's visit to India is expected to provide participants of the industry with a complete assessment of the business potential in Malaysia and strengthen Indian companies' ability to identify and exploit business opportunities there. Fresh collaboration announcements are expected from the meetings scheduled with key players of the Indian biotechnology and life sciences companies.
BiotechCorp has already entered into partnership with Manipal Education and Medical Group of India, while the Chennai-based Malladi Drugs & Pharmaceuticals Ltd has announced plans to invest in the region to tap business opportunities.
"We currently have global investors from India, Britain, France, Germany, Italy, Belgium, US, China, Japan, Taiwan, Hong Kong, Singapore, Thailand, Australia and New Zealand. All of these investors continue to take a very positive view of Malaysia as a rapidly developing biotechnology hub. Even in present circumstances - there is still a good measure of resilience from external shocks, which the Malaysian economy still offer in comparison to our neighboring countries," said, Selvam Ramaraj, senior vice president, industry development division (Healthcare), BiotechCorp.
"Biotechnology has been identified as one of the key drivers for growth by the Malaysian government and will continue to be supported as one of the new sources of growth not only for the nation's economy, but as an enabler to move conventional sectors up the value chain. Kuala Lumpur-based BiotechCorp was established in 2005 to play the leading role in building the biotechnology business in Malaysia by creating a conductive environment and actively promoting foreign direct investments in biotechnology," he added.
In the 2009 budget, the Malaysian government has allocated a RM13.7 billion (US$3 billion) to enhance healthcare, which include increasing the supply of medicine, intensifying research and enforcement activities as well as further strengthening the growth of healthcare biotechnology. This is in line with BiotechCorp's BioNexus status, which is given to companies to enjoy a set of incentives and privileges contained within the BioNexus Bill of Guarantee.
Some of the incentives offered via the BioNexus status include: Freedom of ownership to source funds globally and to bring in knowledge workers; 100 per cent income tax exemption for 10 years commencing from the first year the company derives profit or investment tax allowance of 100 per cent on the qualifying capital expenditure incurred within a period of 5 years; Tax exemption on dividends distributed by a BioNexus company; Exemption of import duty and sales tax on raw materials/components and machinery/equipment; Double deduction on expenditure incurred for R&D
To meet the growing needs to examine much larger tissue samples, researchers at the University of Strathclyde in Glasgow, Scotland has developed the 70cm mesolens, with its 8cm diameter, the only device in the world which will be able to capture details in organisms which...
As a part of the President’s fiscal year (FY) 2013 budget the U.S. Food and Drug Administration has asked a budget of $4.5 billion on medical product development, protect patients and ensure safety of the food supply to support public health.
USA-based Medivation (NASDAQ: MDVN) and global drugs behemoth Pfizer (NYSE: PFE) have finally decided to discontinue the development of Dimebon also known as latrepirdine, for all indications and will terminate the ongoing open label extension study in Alzheimer's disease.
Antares Pharma has recently announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. The companies did not disclose specifics of the deal.
Humana, one of the nation's largest health care companies, and Pfizer, the world's largest biopharmaceutical company, have recently linked together to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other population....
Leading Pharma industry experts plan to be at the Pharma Market Research Conference which takes place on February 7-8 at the Hilton Parsippany Hotel in New Jersey.
Date: 21 Feb 2012 - 23 Feb 2012 Place: Florence, Italy Organized by: ECDC,Istituto Superiore di Sanita’ (ISS) and Agenzia Sanitaria Locale (ASL) Epidemiological methods applied to vaccine preventable diseases is a 3 day workshop which will focus on building the capacity to organize, manage,...
Bangalore-based biopharmaceutical start-up Biovel Lifesciences is looking to exit from the life sciences space and is keen for an early outright buyout. Biovel has been in dialogue with several companies including Ranbaxy, Avesthagen, Shantha Biotechnics Ltd and Orchid Chemicals, it is learnt.
Sanofi-aventis, the world's leading vaccine manufacturer, officially launched the construction of a new Sanofi Pasteur vaccine manufacturing centre in Neuville-sur-Saône, France.
The pharmaceutical and biotechnology industry is in the process of consolidating and down-sizing while trying to maintain R&D productivity. Small and medium-sized companies are trying to make the most of available opportunities in niche segments.
Last year, the Biotech industry as a whole achieved much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The...
Lupin Ltd, one of the top five domestic pharmaceutical companies, plans to revamp its drug research programme and foray into novel biotech and reverse engineering of biotech drugs (or biosimilars).
Ahmedabad based Contract Research and Manufacturing Services (CRAMS) major Dishman Pharmaceuticals and Chemicals Ltd has entered into a strategic alliance with California based biotechnology firm Codexis, Inc. that will allow Dishman to use of Codexis' proprietary enzymatic biocatalysis technology to manufacture intermediates and active pharmaceutical...
Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery and development in the life sciences industry, announced the extension of its agreement with sanofi-aventis for the licence of the DDI Predict 2009 Edition application.
According to a report, UK based Pharma company AstraZeneca PLC (ADR) (NYSE: AZN), and US based Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) plan to develop a drug to treat rheumatoid arthritis.
Alliance Pharma (AIM: APH) said it has agreed a significantly earnings enhancing acquisition, buying a portfolio of 18 prescription products. The company has conditionally agreed to acquire certain assets of privately owned Cambridge Laboratories in a deal worth between £14.3m and £16.4m, plus an additional...
1.Indian Institute of Toxicology - Indian Institute of Toxicology (IIT) is one of the pioneers, independent Contract Research Organization (CRO) engaged in toxicology and has been in the business for the past 25 Years. The institute is committed to excellence, which is borne out of a State-of-art infrastructure & technical skills in the field of Toxicology Studies.... [English]-[French]-[Spanish]
EMERGING MARKETS
The collapse of the property market has left the economy with a huge hole that will be difficult to fill. One of the few sectors that offers hope of growth is the pharmaceutical industry, with senior executives convinced that genuine opportunities remain for Ireland Inc....
Many shifting focus to emerging economies in struggle to stay afloatMajor Japanese pharmaceutical makers are expediting projects to construct plants and expand sales channels in emerging economies, such as China and India.
Pharma major Ranbaxy Laboratories today said it has launched a new dermatological product Lulifin in the Indian market. This follows a strategic in-licensing agreement with Summit Pharmaceuticals International Corporation, Japan, Ranbaxy said.
DR REDDY’S Laboratories plans to buy brands in Russia and introduce new products in India as it plans to scale up businesses in key emerging markets, a top company executive said.
Brand ambassador Kajol Devgan promotes the kiss of good health. Expanding its footprint in India, Yakult Danone India (P) Ltd. announced its expansion by launching Yakult, a global probiotic health drink in the city today.
Indian Pharma Companies Eye High Potency API Market Pie The Indian Active Pharmaceutical Ingredient (API) Industry is fast developing though many challenges exist as it....[English]-[French]-[Spanish]
Indian Biogenerics Firms Poised to Storm Western Markets With blockbuster first-generation biotherapeutics developed in the West are losing patent protection, Indian biopharma...[English] [French] [Spanish]
CLINICAL TRIALS
Researchers from Colorado Cancer Center have found that grape seed extract can destroy cancer cell which target the head and neck of human body. The study shows that Grape Seed extract lowers the growth rate of certain Cancers by up to 67%.
A study recently has proved that stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack. The cells, called cardiosphere-derived stem cells, regrew damaged heart muscles and reversed scarring one year later, the authors say....
A new study has been found by The University of Texas Health Science Center at San Antonio that Bat plant, or Tacca chantrieri, could be used to fight cancer.
Scientist have again achieved a great success by developing a new drug KG5, which kills off cancer and also could wipe out some of the most deadly forms of the disease. It also acts by cutting off the blood supply to tumours.This drug is expected...
Franchise India Holdings limited in association with Francorp and Medium Healthcare Consulting Pvt Ltd has organized a two day workshop on Business of Healthcare, Wellness and Beauty at Taj Lands End, Mumbai. On the occasion India’s First Healthcare, Wellness and Beauty Franchising Report was launched...
In what seems to be an alarming situation for the national health, India ranks highest in the list of Tuberculosis (TB) inflicted countries worldwide, as unveiled by the Union Ministry of Chemicals and Fertilizers.
Recently U.S. Food and Drug Administration has approved INLYTA(R) axitinib, a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) who have not responded to another drug for this type of cancer.
Dishman Pharmaceuticals & Chemicals Ltd, a contract research & manufacturing services (CRAM) major, received the US Food and Drug Administration (USFDA) nod for producing Active Pharmaceutical Ingredients (API) at its Naroda facility here.
US-based Zydus Pharmaceuticals, a subsidiary of Zydus Cadila, has received final approval from the US Food and Drug Administration (USFDA) to market Ramipril tablets, in the strengths of 1.25 mg, 2.5 mg, 5 mg and 10 mg.
In a move to boost the bilateral trade relationship between Malaysia and India, Malaysian Biotechnology Corporation (BiotechCorp), the lead development agency for the biotechnology industry in Malaysia, kicked off their first business development engagement for 2009 in Hyderabad and Chennai with the Indian media members and industry participants. The latest updates on the Indian-Malaysian investment initiatives were shared to address the current challenging economic climate. 
Indian Pharma Companies Eye High Potency API Market Pie
Indian Biogenerics Firms Poised to Storm Western Markets
